503 related articles for article (PubMed ID: 28219450)
1. Evaluation of serum D-dimer, fibrinogen, and CA19-9 for postoperative monitoring and survival prediction in resectable pancreatic carcinoma.
Cao J; Fu Z; Gao L; Wang X; Cheng S; Wang X; Ren H
World J Surg Oncol; 2017 Feb; 15(1):48. PubMed ID: 28219450
[TBL] [Abstract][Full Text] [Related]
2. Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.
Sugiura T; Uesaka K; Kanemoto H; Mizuno T; Sasaki K; Furukawa H; Matsunaga K; Maeda A
J Gastrointest Surg; 2012 May; 16(5):977-85. PubMed ID: 22411488
[TBL] [Abstract][Full Text] [Related]
3. Postoperative serum CEA and CA125 levels are supplementary to perioperative CA19-9 levels in predicting operative outcomes of pancreatic ductal adenocarcinoma.
Xu HX; Liu L; Xiang JF; Wang WQ; Qi ZH; Wu CT; Liu C; Long J; Xu J; Ni QX; Yu XJ
Surgery; 2017 Feb; 161(2):373-384. PubMed ID: 27838102
[TBL] [Abstract][Full Text] [Related]
4. Normalization of CA19-9 following resection for pancreatic ductal adenocarcinoma is not tantamount to being cured?
Chen T; Zhang MG; Yu XJ; Liu L
Asian Pac J Cancer Prev; 2015; 16(2):661-6. PubMed ID: 25684504
[TBL] [Abstract][Full Text] [Related]
5. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
6. The prognostic evaluation of CA19-9, D-dimer and TNFAIP3/A20 in patients with pancreatic ductal adenocarcinoma.
Xu P; Wang X; Qian J; Li Z; Yao J; Xu A
Medicine (Baltimore); 2021 Feb; 100(6):e24651. PubMed ID: 33578593
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum CA19-9 level is a promising predictor for poor prognosis in patients with resectable pancreatic ductal adenocarcinoma: a pilot study.
Dong Q; Yang XH; Zhang Y; Jing W; Zheng LQ; Liu YP; Qu XJ
World J Surg Oncol; 2014 Jun; 12():171. PubMed ID: 24890327
[TBL] [Abstract][Full Text] [Related]
8. Preoperative CA 19-9 kinetics as a prognostic variable in radiographically resectable pancreatic adenocarcinoma.
Brown EG; Canter RJ; Bold RJ
J Surg Oncol; 2015 Mar; 111(3):293-8. PubMed ID: 25330934
[TBL] [Abstract][Full Text] [Related]
9. Preoperative predictors for early recurrence of resectable pancreatic cancer.
Nishio K; Kimura K; Amano R; Yamazoe S; Ohrira G; Nakata B; Hirakawa K; Ohira M
World J Surg Oncol; 2017 Jan; 15(1):16. PubMed ID: 28069033
[TBL] [Abstract][Full Text] [Related]
10. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma.
Ferrone CR; Finkelstein DM; Thayer SP; Muzikansky A; Fernandez-delCastillo C; Warshaw AL
J Clin Oncol; 2006 Jun; 24(18):2897-902. PubMed ID: 16782929
[TBL] [Abstract][Full Text] [Related]
11. Can preoperative CA19-9 and CEA levels predict the resectability of patients with pancreatic adenocarcinoma?
Kim YC; Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI; Shin JH
J Gastroenterol Hepatol; 2009 Dec; 24(12):1869-75. PubMed ID: 19686409
[TBL] [Abstract][Full Text] [Related]
12. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
[TBL] [Abstract][Full Text] [Related]
13. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time.
Rieser CJ; Zenati M; Hamad A; Al Abbas AI; Bahary N; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Nov; 25(12):3483-3491. PubMed ID: 29786131
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of CEA, CA19-9, CA72-4 and CA125 in gastric cancer patients with neoadjuvant chemotherapy.
Sun Z; Zhang N
World J Surg Oncol; 2014 Dec; 12():397. PubMed ID: 25543664
[TBL] [Abstract][Full Text] [Related]
15. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy.
Hartwig W; Strobel O; Hinz U; Fritz S; Hackert T; Roth C; Büchler MW; Werner J
Ann Surg Oncol; 2013 Jul; 20(7):2188-96. PubMed ID: 23247983
[TBL] [Abstract][Full Text] [Related]
16. Relationship between S100A4 protein expression and pre-operative serum CA19.9 levels in pancreatic carcinoma and its prognostic significance.
Jia F; Liu M; Li X; Zhang F; Yue S; Liu J
World J Surg Oncol; 2019 Sep; 17(1):163. PubMed ID: 31526392
[TBL] [Abstract][Full Text] [Related]
17. Cancer outcomes are independent of preoperative CA 19-9 in anatomically resectable pancreatic ductal adenocarcinoma: A retrospective cohort analysis.
Kim JK; DePeralta DK; Ogami T; Denbo JW; Pimiento J; Hodul PJ; Malafa MP; Kim DW; Fleming JB; Powers BD
J Surg Oncol; 2020 Nov; 122(6):1074-1083. PubMed ID: 32673436
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the prognostic impact of pre- and post-operative CA19-9, SPan-1, and DUPAN-II levels in patients with pancreatic carcinoma.
Kondo N; Murakami Y; Uemura K; Nakagawa N; Takahashi S; Ohge H; Sueda T
Pancreatology; 2017; 17(1):95-102. PubMed ID: 27746094
[TBL] [Abstract][Full Text] [Related]
19. Preoperative high level of D-dimers predicts unresectability of pancreatic head cancer.
Durczynski A; Kumor A; Hogendorf P; Szymanski D; Grzelak P; Strzelczyk J
World J Gastroenterol; 2014 Sep; 20(36):13167-71. PubMed ID: 25278712
[TBL] [Abstract][Full Text] [Related]
20. Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.
Berger AC; Meszoely IM; Ross EA; Watson JC; Hoffman JP
Ann Surg Oncol; 2004 Jul; 11(7):644-9. PubMed ID: 15197014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
